Goldman Sachs’s Genprex GNPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-24
Closed -$22.5K – 6200
2024
Q4
$22.5K Buy
+24
New +$31.5K ﹤0.01% 5891
2022
Q3
– Hold
0
– -$30K – 6380
2022
Q2
– Sell
-3
Closed -$211K – 6123
2022
Q1
$275K Buy
3
+2
+200% +$195K ﹤0.01% 5710
2021
Q4
$29K Buy
+1
New +$83.4K ﹤0.01% 6329
2021
Q3
– Sell
-1
Closed -$86K – 6332
2021
Q2
$86K Buy
+1
New +$164K ﹤0.01% 5974
2021
Q1
– Hold
0
– – – 5875
2020
Q4
– Hold
0
– -$46K – 5567
2020
Q3
– Sell
-1
Closed -$158K – 5200
2020
Q2
$134K Buy
+1
New +$122K ﹤0.01% 4913
2019
Q4
– Sell
-1
Closed -$21K – 5291
2019
Q3
$21K Buy
+1
New +$42.2K ﹤0.01% 5108

Other funds holding GNPX

Goldman Sachs's GNPX Position: Q1 2025 in Review

Goldman Sachs sold out of Genprex (GNPX) in Q1 2025, closing a stake of 24 shares — an estimated $22.5K sold.

Goldman Sachs first reported a position in GNPX in Q3 2019 and held it in 6 quarters. The position peaked at $275K in Q1 2022. 14 funds tracked by Wall St. Rank hold GNPX as of Q1 2025.

  • Goldman Sachs reported no remaining Genprex position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 24 Genprex shares in Q1 2025, an estimated $22.5K.
  • Goldman Sachs first reported a position in Genprex in Q3 2019 and held it in 6 quarters.
  • Goldman Sachs's Genprex position peaked at $275K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Genprex as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.